SinoMab BioScience Limited

3681

HK0000544194

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
1.9 ^HKD	0.00%		0.00%	+13.10%

Mar. 25	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

SinoMab BioScience : (i) CONNECTED TRANSACTION UNDER THE SUPPLEMENTAL AGREEMENT TO THE BTK TRANSFER AND COLLABORATION AGREEMENT (ii) CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS UNDER THE LICENSE AGREEMENT

November 23, 2021 at 03:59 am EST

[title]	[date]	[link]	[market]	[doc type]	[stock code]	[stock name]
(i) CONNECTED TRANSACTION UNDER THE SUPPLEMENTAL AGREEMENT TO THE BTK TRANSFER AND COLLABORATION AGREEMENT (ii) CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS UNDER THE LICENSE AGREEMENT	23/11/2021 16:49	Link	SEHK	htm	03681	SINOMAB BIO-B
Discloseable Transaction - Provision of Financial Assistance	23/11/2021 16:47	Link	SEHK	pdf	01669	GIC GROUP
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section	23/11/2021 16:46	Link	SEHK	htm	06066	CSC
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS	23/11/2021 16:44	Link	SEHK	pdf	02008	PHOENIX TV
Notification Letter and Request Form to Non-Registered Shareholders	23/11/2021 16:43	Link	SEHK	pdf	02309	BIRMINGHAM SPTS
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE STRATEGIC PARTNERSHIP WITH XPENG	23/11/2021 16:42	Link	SEHK	pdf	00881	ZHONGSHENG HLDG
ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES	23/11/2021 16:42	Link	SEHK	pdf	00604	SHENZHEN INVEST
SHARE OPTION SCHEME	23/11/2021 16:42	Link	SEHK	pdf	03888	KINGSOFT
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section	23/11/2021 16:41	Link	SEHK	htm	02880	LIAONING PORT
CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE UNDER THE COMPANIES ORDINANCE AND AUTHORISED REPRESENTATIVE UNDER THE LISTING RULES	23/11/2021 16:41	Link	SEHK	pdf	01849	AM GROUP
NOTICE OF ANNUAL GENERAL MEETING	23/11/2021 16:41	Link	SEHK	pdf	02309	BIRMINGHAM SPTS
Next Day Disclosure Return	23/11/2021 16:40	Link	SEHK	pdf	00005	HSBC HOLDINGS
FORM OF PROXY	23/11/2021 16:39	Link	SEHK	pdf	02309	BIRMINGHAM SPTS
NEXT DAY DISCLOSURE RETURN	23/11/2021 16:39	Link	SEHK	pdf	00098	XINGFA ALUM
INSIDE INFORMATION STATUTORY DEMAND	23/11/2021 16:38	Link	SEHK	pdf	00706	BEAUTI C HOLD
RESIGNATION OF NON-EXECUTIVE DIRECTOR	23/11/2021 16:38	Link	SEHK	pdf	02008	PHOENIX TV
FORM OF PROXY FOR USE AT THE EXTRAORDINARY GENERAL MEETING (the ''EGM'') TO BE HELD ON THURSDAY, 9 DECEMBER 2021 (or at any adjournment thereof)	23/11/2021 16:38	Link	SEHK	pdf	03888	KINGSOFT
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021 AND THE UNAUDITED KEY OPERATIONAL DATA FROM 1 OCTOBER TO 18 NOVEMBER 2021	23/11/2021 16:37	Link	SEHK	pdf	01929	CHOW TAI FOOK
GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	23/11/2021 16:37	Link	SEHK	pdf	02309	BIRMINGHAM SPTS
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD AT THEATER R1, 10/F, UNITED CENTRE, 95 QUEENSWAY, ADMIRALTY, HONG KONG ON TUESDAY, 14 DECEMBER 2021 AT 10:00 A.M.	23/11/2021 16:37	Link	SEHK	pdf	03681	SINOMAB BIO-B

Attachments

Original Link
Original Document
Permalink

Disclaimer

SinoMab BioScience Ltd. published this content on 23 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 November 2021 08:58:07 UTC.

Latest news about SinoMab BioScience Limited

SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	Feb. 07	CI
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	Jan. 15	MT
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	Dec. 15	MT
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	Nov. 28	MT
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	Nov. 27	CI
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	Nov. 15	MT
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	Nov. 15	CI
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	23-09-11	MT
Sinomab Bioscience Limited announces Change of Non-Executive Directors	23-09-06	CI
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	23-09-05	MT
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	23-09-05	MT
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	23-09-05	CI
SinoMab Bioscience to Shrink Loss in H1	23-08-22	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	23-08-15	MT
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	23-08-14	CI
Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE	23-06-12	CI
Chinese Regulator Accepts SinoMab's Investigational New Drug Application for Asthma Treatment	23-05-21	MT
SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China	23-05-21	CI
SinoMab Bioscience Achieves Primary Endpoints for Phase III Clinical Study of Rheumatoid Arthritis Treatment; Shares Cimb 4%	23-04-27	MT
SinoMab BioScience Limited Announces Phase III Clinical Trial of its Product SM03 (Suciraslimab) Achieves the Primary Endpoint for Rheumatoid Arthritis	23-04-26	CI
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
SinoMab Bioscience Unit's Rent in Haiyao Industrial Park Rises to 9.4 Million Yuan	22-12-02	MT
Hainan Sinomab Enters into A Supplemental Lease Agreement with Haikou Pharma Pursuant to Which the Annual Rental of the Property	22-12-01	CI

Chart SinoMab BioScience Limited

Duration

Period

More charts

Company Profile

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Companyâs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogrenâs syndrome (SS) and other immunological diseases.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SINOMAB BIOSCIENCE LIMITED	+13.10%	265M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B